North America Contrast and Imaging Agents in Interventional X-ray Market Industry Trends Forecast to 2026

January 2019 | 100 pages | ID: NFE26699B76EN
Data Bridge Market Research

Abstracts

North America contrast and imaging agents in interventional X-ray market is projected to register a healthy CAGR of 5.3% in the forecast period 2019 to 2026. The new market report contains data for historic years 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation

By Agent Type (Iodinated Contrast Media, Barium-Based Contrast Media, Microbubble Contrast Media, Gold Nanoparticle Contrast Agents, Others), Application (Cardiology, Gastroenterology, Neurology, Oncology, Urology, General Surgery), End User (Imaging Centers, Hospital, Clinics, Diagnostic Center, Ambulatory Surgical Centers, Private Practices), Country (U.S., Canada and Mexico)

Major growing sectors under the market segmentation are as follows:

• In agent type, iodinated contrast media is dominating as well as the fastest growing segment in this market.
• In application, cardiology is dominating as well as the fastest growing segment in this market.
• In end user, imaging centers is dominating as well as the fastest growing segment in this market.

Market Players

The Key Market Players for North America contrast and imaging agents in interventional X-ray market are listed below:

• General Electric Company
• BRACCO
• Guerbet
• Lantheus Medical Imaging, Inc.
• FUJIFILM VisualSonics Inc.
• Jodas Expoim
• TAEJOON PHARM
• Unijules Life Sciences Ltd.
• J.B.Chemicals & Pharmaceuticals Ltd.
• iMAX
• Novalek Pharmaceuticals Pvt. Ltd.
• Nano Therapeutics Pvt Ltd
• Others

Contents

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED
2.2 GEOGRAPHIC SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 RESEARCH METHODOLOGY
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET CHALLENGE MATRIX
2.8 MARKET APPLICATION COVERAGE GRID
2.9 DBMR VENDOR SHARE ANALYSIS
2.10 SECONDARY SOURCES
2.11 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS
  3.1.1 RISING NUMBER OF CHRONIC DISEASES
  3.1.2 RISING AGING POPULATION
  3.1.3 GROWING NUMBER OF DIAGNOSTIC CENTERS
  3.1.4 INCREASE IN THE RESEARCH AND DEVELOPMENTAL ACTIVITIES OF CONTRAST AGENTS
3.2 RESTRAINT
  3.2.1 SIDE EFFECTS ASSOCIATED WITH CONTRAST AGENTS
3.3 OPPORTUNITIES
  3.3.1 RISING HEALTHCARE EXPENDITURE
  3.3.2 INCREASE IN NUMBER OF PUBLIC AND PRIVATE HOSPITALS
3.4 CHALLENGE
  3.4.1 LACK OF AWARENESS REGARDING THE PROPER DOSAGE OF CONTRAST AGENT

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 KEY PRIMARY INSIGHTS

7 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY AGENT TYPE

7.1 OVERVIEW
7.2 IODINATED CONTRAST MEDIA
7.3 BARIUM-BASED CONTRAST MEDIA
7.4 MICROBUBBLE CONTRAST MEDIA
7.5 GOLD NANOPARTICLE CONTRAST AGENTS
7.6 OTHERS

8 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY APPLICATION

8.1 OVERVIEW
8.2 CARDIOLOGY
  8.2.1 PERCUTANEOUS CORONARY INTERVENTION
  8.2.2 STRUCTURAL HEART DISEASE
  8.2.3 CONGENITAL HEART DISEASE
  8.2.4 ELECTROPHYSIOLOGY
8.3 GASTROENTEROLOGY
8.4 NEUROLOGY
8.5 ONCOLOGY
8.6 UROLOGY
8.7 GENERAL SURGERY

9 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY END USER

9.1 OVERVIEW
9.2 IMAGING CENTERS
9.3 HOSPITAL
9.4 CLINICS
9.5 DIAGNOSTIC CENTER
9.6 AMBULATORY SURGICAL CENTERS
9.7 PRIVATE PRACTICES

10 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY GEOGRAPHY

10.1 NORTH AMERICA
  10.1.1 U.S.
  10.1.2 CANADA
  10.1.3 MEXICO

11 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, COMPANY LANDSCAPE

11.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

12 COMPANY PROFILES

12.1 BRACCO
  12.1.1 COMPANY SNAPSHOT
  12.1.2 GEOGRAPHICAL PRESENCE
  12.1.3 COMPANY SHARE ANALYSIS
  12.1.4 PRODUCT PORTFOLIO
  12.1.5 RECENT DEVELOPMENTS
12.2 GENERAL ELECTRIC COMPANY
  12.2.1 COMPANY SNAPSHOT
  12.2.2 REVENEUE ANALYSIS
  12.2.3 COMPANY SHARE ANALYSIS
  12.2.4 PRODUCT PORTFOLIO
  12.2.5 RECENT DEVELOPMENTS
12.3 GUERBET
  12.3.1 COMPANY SNAPSHOT
  12.3.2 REVENEUE ANALYSIS
  12.3.3 COMPANY SHARE ANALYSIS
  12.3.4 PRODUCT PORTFOLIO
  12.3.5 RECENT DEVELOPMENTS
12.4 FUJIFILM VISUALSONICS INC.
  12.4.1 COMPANY SNAPSHOT
  12.4.2 GEOGRAPHICAL PRESENCE
  12.4.3 PRODUCT PORTFOLIO
  12.4.4 RECENT DEVELOPMENT
12.5 IMAX
  12.5.1 COMPANY SNAPSHOT
  12.5.2 GEOGRAPHICAL PRESENCE
  12.5.3 PRODUCT PORTFOLIO
  12.5.4 RECENT DEVELOPMENT
12.6 J.B. CHEMICALS & PHARMACEUTICALS LTD.
  12.6.1 COMPANY SNAPSHOT
  12.6.2 REVENUE ANALYSIS
  12.6.3 PRODUCT PORTFOLIO
  12.6.4 RECENT DEVELOPMENT
12.7 JODAS EXPOIM
  12.7.1 COMPANY SNAPSHOT
  12.7.2 GEOGRAPHICAL PRESENCE
  12.7.3 PRODUCT PORTFOLIO
  12.7.4 RECENT DEVELOPMENTS
12.8 LANTHEUS MEDICAL IMAGING, INC.
  12.8.1 COMPANY SNAPSHOT
  12.8.2 REVENUE ANALYSIS
  12.8.3 PRODUCT PORTFOLIO
  12.8.4 RECENT DEVELOPMENTS
12.9 NANO THERAPEUTICS PVT. LTD.
  12.9.1 COMPANY SNAPSHOT
  12.9.2 GEOGRAPHICAL PRESENCE
  12.9.3 PRODUCT PORTFOLIO
  12.9.4 RECENT DEVELOPMENT
12.10 NOVALEK PHARMACEUTICALS PVT. LTD.
  12.10.1 COMPANY SNAPSHOT
  12.10.2 GEOGRAPHICAL PRESENCE
  12.10.3 PRODUCT PORTFOLIO
  12.10.4 RECENT DEVELOPMENT
12.11 TAEJOON PHARM
  12.11.1 COMPANY SNAPSHOT
  12.11.2 GEOGRAPHICAL PRESENCE
  12.11.3 PRODUCT PORTFOLIO
  12.11.4 RECENT DEVELOPMENT
12.12 UNIJULES LIFE SCIENCES LTD.
  12.12.1 COMPANY SNAPSHOT
  12.12.2 PRODUCT PORTFOLIO
  12.12.3 RECENT DEVELOPMENT

13 QUESTIONNAIRE

14 RELATED REPORTS

List Of Tables

LIST OF TABLES

Table 1 TOTAL AGEING POPULATION IN TURKEY AND IRAN
Table 2 NUMBER OF DIAGNOSTIC IMAGING EQUIPMENT IN CANADA (2007 & 2017)
Table 3 RESEARCH AND DEVELOPMENT EXPENDITURE FOR COMPANIES (USD MILLION) (2016 & 2017)
Table 4 AMOUNT OF CONTRAST MEDIA TO BE TAKEN AS PER PATIENT’S WEIGHT
Table 5 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY AGENT TYPE, 2017-2026 (USD MILLION)
Table 6 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, IODINATED CONTRAST MEDIA, BY REGION, 2017-2026 (USD MILLION)
Table 7 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BARIUM-BASED CONTRAST MEDIA, BY REGION, 2017-2026 (USD MILLION)
Table 8 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, MICROBUBBLE CONTRAST MEDIA, BY REGION, 2017-2026 (USD MILLION)
Table 9 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, GOLD NANOPARTICLE CONTRAST AGENTS, BY REGION, 2017-2026 (USD MILLION)
Table 10 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, OTHERS, BY REGION, 2017-2026 (USD MILLION)
Table 11 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
Table 12 NORTH AMERICA CARDIOLOGY CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
Table 13 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, CARDIOLOGY, BY REGION, 2017-2026 (USD MILLION)
Table 14 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, GASTROENTEROLOGY, BY REGION, 2017-2026 (USD MILLION)
Table 15 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, NEUROLOGY, BY REGION, 2017-2026 (USD MILLION)
Table 16 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, ONCOLOGY, BY REGION, 2017-2026 (USD MILLION)
Table 17 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, UROLOGY, BY REGION, 2017-2026 (USD MILLION)
Table 18 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, GENERAL SURGERY, BY REGION, 2017-2026 (USD MILLION)
Table 19 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY END USER, 2017-2026 (USD MILLION)
Table 20 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, IMAGING CENTERS, BY REGION, 2017-2026 (USD MILLION)
Table 21 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, HOSPITAL, BY REGION, 2017-2026 (USD MILLION)
Table 22 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, CLINICS, BY REGION, 2017-2026 (USD MILLION)
Table 23 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, DIAGNOSTIC CENTER, BY REGION, 2017-2026 (USD MILLION)
Table 24 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, AMBULATORY SURGICAL CENTERS, BY REGION, 2017-2026 (USD MILLION)
Table 25 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, PRIVATE PRACTICES, BY REGION, 2017-2026 (USD MILLION)
Table 26 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
Table 27 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY AGENT TYPE, 2017-2026 (USD MILLION)
Table 28 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
Table 29 NORTH AMERICA CARDIOLOGY IN CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
Table 30 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY END USER, 2017-2026 (USD MILLION)
Table 31 U.S. CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY AGENT TYPE, 2017-2026 (USD MILLION)
Table 32 U.S. CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
Table 33 U.S. CARDIOLOGY IN CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
Table 34 U.S. CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY END USER, 2017-2026 (USD MILLION)
Table 35 CANADA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY AGENT TYPE, 2017-2026 (USD MILLION)
Table 36 CANADA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
Table 37 CANADA CARDIOLOGY IN CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
Table 38 CANADA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY END USER, 2017-2026 (USD MILLION)
Table 39 MEXICO CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY AGENT TYPE, 2017-2026 (USD MILLION)
Table 40 MEXICO CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
Table 41 MEXICO CARDIOLOGY IN CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
Table 42 MEXICO CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY END USER, 2017-2026 (USD MILLION)

List Of Figures

LIST OF FIGURES

Figure 1 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: SEGMENTATION
Figure 2 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: DATA TRIANGULATION
Figure 3 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: DROC ANALYSIS
Figure 4 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: BOTTOM UP APPROACH
Figure 5 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: TOP DOWN APPROACH
Figure 6 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: INTERVIEW DEMOGRAPHICS
Figure 7 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: THE MARKET CHALLENGE MATRIX
Figure 8 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: MARKET APPLICATION COVERAGE GRID
Figure 9 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: DBMR VENDOR SHARE ANALYSIS
Figure 10 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET
Figure 11 AGEING POPULATION OF CANADA (% OF TOTAL)
Figure 12 TOTAL POPULATION OF AGES 65 AND ABOVE (% OF TOTAL) IN 2015 & 2016
Figure 13 TOTAL NUMBER OF PHYSICIANS IN CANADA, (2015 & 2018)
Figure 14 TOTAL HEALTH SPENDING PER CANADIAN (USD) (2017 & 2018)
Figure 15 TOTAL CANADA HEALTH EXPENDITURE, BY SOURCE OF FINANCE, 2016 (USD BILLIONS)
Figure 16 HEALTH EXPENDITURE PER CAPITA IN PPP INTERNATIONAL USD
Figure 17 TOTAL NUMBER OF HOSPITALS IN CANADA (2015& 2016)
Figure 18 NORTH AMERICA IS ANTICIPATED TO DOMINATE CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET AND ASIA PACIFIC IS ESTIMATED TO BE INCREASING WITH THE STRONG CAGR IN THE FORECAST PERIOD FROM 2019 TO 2026
Figure 19 RISING NUMBER OF CHRONIC DISEASES, RISING AGING POPULATION, GROWING NUMBER OF DIAGNOSIC CENTRES AND INCREASE IN THE RESEARCH AND DEVELOPMENTAL ACTIVITIES OF CONTRAST AGENTS ARE DRIVING THE MARKET FOR NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY IN THE FORECAST PERIOD OF 2019 TO 2026
Figure 20 IODINATED CONTRAST MEDIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET IN 2019 & 2026
Figure 21 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: BY AGENT TYPE, 2018
Figure 22 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: BY APPLICATION, 2018
Figure 23 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: BY END USER, 2018
Figure 24 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET SNAPSHOT (2018)
Figure 25 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: BY COUNTRY (2018)
Figure 26 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: BY COUNTRY (2019 & 2026)
Figure 27 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: BY COUNTRY (2018 & 2026)
Figure 28 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: BY AGENT TYPE (2019 - 2026)
Figure 29 NORTH AMERICA CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET: COMPANY SHARE 2018 (%)